ROVI announces the agreement to market Hirobriz Breezhaler y Ulunar Breezhaler en España


No votes yet
 
Related
Recruitment of two doctors for the R&D area under the Torres Quevedo Programme 2020
ROVI is a company committed to innovation, allowing it to safeguard its portfolio composed of over 500 patent dossiers, 408 of which have...
1 min
30/10/2020
ROVI holds its 2020 General Shareholders' Meeting
Today, Laboratorios Farmacéuticos Rovi, S.A. held its General Shareholders’ Meeting, where the year 2019, marked by significant growth, was...
5 min
20/10/2020